- About this Journal ·
- Abstracting and Indexing ·
- Aims and Scope ·
- Annual Issues ·
- Article Processing Charges ·
- Author Guidelines ·
- Bibliographic Information ·
- Citations to this Journal ·
- Contact Information ·
- Editorial Board ·
- Editorial Workflow ·
- Free eTOC Alerts ·
- Publication Ethics ·
- Recently Accepted Articles ·
- Reviewers Acknowledgment ·
- Submit a Manuscript ·
- Subscription Information ·
- Table of Contents
BioMed Research International
Volume 2013 (2013), Article ID 276808, 9 pages
Frataxin mRNA Isoforms in FRDA Patients and Normal Subjects: Effect of Tocotrienol Supplementation
1Department of Experimental, Diagnostic and Specialty Medicine, University of Bologna, 40126 Bologna, Italy
2Department of Pharmaceutical Sciences, University of Ferrara, 44100 Ferrara, Italy
3ANFFAS ONLUS Macerata, 62100 Macerata, Italy
4Child Neurology and Psychiatry Unit, IRCCS Institute of Neurological Sciences of Bologna, Bologna, 40100 Bologna, Italy
5Biocomputing Group, CIRI-Health Science and Technology, Department of Biology, Bologna 40126, Italy
Received 15 April 2013; Revised 6 August 2013; Accepted 17 August 2013
Academic Editor: Chen-Hsiung Hung
Copyright © 2013 Provvidenza Maria Abruzzo et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
- M. B. Delatycki, R. Williamson, and S. M. Forrest, “Friedreich ataxia: an overview,” Journal of Medical Genetics, vol. 37, no. 1, pp. 1–8, 2000.
- G. de Michele, F. Perrone, A. Filla et al., “Age of onset, sex, and cardiomyopathy as predictors of disability and survival in Friedreich's disease: a retrospective study on 119 patients,” Neurology, vol. 47, no. 5, pp. 1260–1264, 1996.
- C. Gellera, B. Castellotti, C. Mariotti et al., “Frataxin gene point mutations in Italian friedreich ataxia patients,” Neurogenetics, vol. 8, no. 4, pp. 289–299, 2007.
- V. Campuzano, L. Montermini, M. D. Moltò et al., “Friedreich's ataxia: autosomal recessive disease caused by an intronic GAA triplet repeat expansion,” Science, vol. 271, no. 5254, pp. 1423–1427, 1996.
- L. Pianese, M. Turano, M. S. Lo Casale et al., “Real time PCR quantification of frataxin mRNA in the peripheral blood leucocytes of friedreich ataxia patients and carriers,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 75, no. 7, pp. 1061–1063, 2004.
- L. Pianese, A. Tammaro, M. Turano, I. de Biase, A. Monticelli, and S. Cocozza, “Identification of a novel transcript of X25, the human gene involved in friedreich ataxia,” Neuroscience Letters, vol. 320, no. 3, pp. 137–140, 2002.
- H. Xia, Y. Cao, X. Dai et al., “Novel frataxin isoforms may contribute to the pathological mechanism of friedreich ataxia,” PLoS ONE, vol. 7, no. 10, Article ID e47847, 2012.
- D. Sirano, R. Shigeta, Y. Chi, M. Ristow, and S. E. Shoelson, “Crystal structure of human frataxin,” The Journal of Biological Chemistry, vol. 275, no. 40, pp. 30753–30756, 2000.
- Y. He, S. L. Alam, S. V. Proteasa et al., “Yeast frataxin solution structure, iron binding, and ferrochelatase interaction,” Biochemistry, vol. 43, no. 51, pp. 16254–16262, 2004.
- M. Nair, S. Adinolfi, C. Pastore, G. Kelly, P. Temussi, and A. Pastore, “Solution structure of the bacterial frataxin ortholog, CyaY: mapping the iron binding sites,” Structure, vol. 12, no. 11, pp. 2037–2048, 2004.
- A. L. Bulteau, H. A. O'Neill, M. C. Kennedy, M. Ikeda-Saito, G. Isaya, and L. I. Szweda, “Frataxin acts as an iron chaperone protein to modulate mitochondrial aconitase activity,” Science, vol. 305, no. 5681, pp. 242–245, 2004.
- O. Stehling, H. Elsässer, B. Brückel, U. Mühlenhoff, and R. Lill, “Iron-sulfur protein maturation in human cells: evidence for a function of frataxin,” Human Molecular Genetics, vol. 13, no. 23, pp. 3007–3015, 2004.
- S. Adinolfi, C. Iannuzzi, F. Prischi et al., “Bacterial frataxin CyaY is the gatekeeper of iron-sulfur cluster formation catalyzed by IscS,” Nature Structural and Molecular Biology, vol. 16, no. 4, pp. 390–396, 2009.
- S. Schmucker, A. Martelli, F. Colin et al., “Mammalian frataxin: an essential function for cellular viability through an interaction with a preformed ISCU/ NFS1/ISD11 iron-sulfur assembly complex,” PLoS ONE, vol. 6, no. 1, Article ID e16199, 2011.
- O. Gakh, S. Park, G. Liu et al., “Mitochondrial iron detoxification is a primary function of frataxin that limits oxidative damage and preserves cell longevity,” Human Molecular Genetics, vol. 15, no. 3, pp. 467–479, 2006.
- R. Santos, S. Lefevre, D. Sliwa, A. Seguin, J. M. Camadro, and E. Lesuisse, “Friedreich ataxia: molecular mechanisms, redox considerations, and therapeutic opportunities,” Antioxidants and Redox Signaling, vol. 13, no. 5, pp. 651–690, 2010.
- T. Meier and G. Buyse, “Idebenone: an emerging therapy for friedreich ataxia,” Journal of Neurology, vol. 256, no. 1, pp. 25–30, 2009.
- S. J. Lagedrost, M. S. J. Sutton, M. S. Cohen et al., “Idebenone in friedreich ataxia cardiomyopathy-results from a 6-month phase III study (IONIA),” The American Heart Journal, vol. 161, no. 3, pp. 639–645, 2011.
- D. R. Lynch, S. L. Perlman, and T. Meier, “A phase 3, double-blind, placebo-controlled trial of idebenone in friedreich ataxia,” Archives of Neurology, vol. 67, no. 8, pp. 941–947, 2010.
- M. L. Jauslin, T. Meier, R. A. Smith, and M. P. Murphy, “Mitochondria-targeted antioxidants protect friedreich ataxia fibroblasts from endogenous oxidative stress more effectively than untargeted antioxidants,” The FASEB Journal, vol. 17, no. 13, pp. 1972–1974, 2003.
- W. Nachbauer, S. Hering, M. Seifert et al., “Effects of erythropoietin on frataxin levels and mitochondrial function in friedreich ataxia—a dose-response trial,” Cerebellum, vol. 10, no. 4, pp. 763–769, 2011.
- S. Boesch, B. Sturm, S. Hering, H. Goldenberg, W. Poewe, and B. Scheiber-Mojdehkar, “Friedreich's ataxia: clinical pilot trial with recombinant human erythropoietin,” Annals of Neurology, vol. 62, no. 5, pp. 521–524, 2007.
- B. B. Aggarwal, C. Sundaram, S. Prasad, and R. Kannappan, “Tocotrienols, the vitamin E of the 21st century: its potential against cancer and other chronic diseases,” Biochemical Pharmacology, vol. 80, no. 11, pp. 1613–1631, 2010.
- S. L. Anderson, J. Qiu, and B. Y. Rubin, “EGCG corrects aberrant splicing of IKAP mRNA in cells from patients with familial dysautonomia,” Biochemical and Biophysical Research Communications, vol. 310, no. 2, pp. 627–633, 2003.
- S. L. Anderson, J. Qiu, and B. Y. Rubin, “Tocotrienols induce IKBKAP expression: a possible therapy for familial dysautonomia,” Biochemical and Biophysical Research Communications, vol. 306, no. 1, pp. 303–309, 2003.
- H. Nakamura, F. Furukawa, A. Nishikawa et al., “Oral toxicity of a tocotrienol preparation in rats,” Food and Chemical Toxicology, vol. 39, no. 8, pp. 799–805, 2001.
- M. Tasaki, T. Umemura, T. Inoue et al., “Induction of characteristic hepatocyte proliferative lesion with dietary exposure of Wistar Hannover rats to tocotrienol for 1 year,” Toxicology, vol. 250, no. 2-3, pp. 143–150, 2008.
- P. Chomczynski and N. Sacchi, “Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction,” Analytical Biochemistry, vol. 162, no. 1, pp. 156–159, 1987.
- P. M. Abruzzo, S. Di Tullio, C. Marchionni et al., “Oxidative stress in the denervated muscle,” Free Radical Research, vol. 44, no. 5, pp. 563–576, 2010.
- K. J. Livak and T. D. Schmittgen, “Analysis of relative gene expression data using real-time quantitative PCR and the 2-ΔΔCT method,” Methods, vol. 25, no. 4, pp. 402–408, 2001.
- M. W. Pfaffl, “A new mathematical model for relative quantification in real-time RT-PCR,” Nucleic Acids Research, vol. 29, no. 9, article e45, 2001.
- N. Eswar, B. Webb, M. A. Marti-Renom et al., “Comparative protein structure modeling using Modeller,” Current Protocols in Bioinformatics, vol. 5, p. 5.6, 2006.
- R. A. Laskowski, M. W. MacArthur, D. S. Moss, and J. M. Thornton, “PROCHECK: a program to check the stereochemical quality of protein structures,” Journal of Applied Crystallography, vol. 26, part 2, pp. 283–291, 1993.
- M. J. Sippl, “Recognition of errors in three-dimensional structures of proteins,” Proteins, vol. 17, no. 4, pp. 355–362, 1993.
- R. Shi, A. Proteau, M. Villarroya et al., “Structural basis for Fe-S cluster assembly and tRNA thiolation mediated by IscS protein-protein interactions,” PLoS Biology, vol. 8, no. 4, Article ID e1000354, 2010.
- G. M. Morris, R. Huey, W. Lindstrom et al., “Software news and updates AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility,” Journal of Computational Chemistry, vol. 30, no. 16, pp. 2785–2791, 2009.
- S. Leidgens, S. de Smet, and F. Foury, “Frataxin interacts with Isu1 through a conserved tryptophan in its β-sheet,” Human Molecular Genetics, vol. 19, no. 2, Article ID ddp495, pp. 276–286, 2009.
- J. S. Armstrong, O. Khdour, and S. M. Hecht, “Does oxidative stress contribute to the pathology of Friedreich's ataxia? A radical question,” The FASEB Journal, vol. 24, no. 7, pp. 2152–2163, 2010.
- D. Marmolino, “Friedreich's ataxia: past, present and future,” Brain Research Reviews, vol. 67, no. 1-2, pp. 311–330, 2011.
- D. Marmolino, F. Acquaviva, M. Pinelli et al., “PPAR-γ agonist azelaoyl PAF increases frataxin protein and mRNA expression. New implications for the friedreich's ataxia therapy,” Cerebellum, vol. 8, no. 2, pp. 98–103, 2009.
- F. Fang, Z. Kang, and C. Wong, “Vitamin E tocotrienols improve insulin sensitivity through activating peroxisome proliferator-activated receptors,” Molecular Nutrition and Food Research, vol. 54, no. 3, pp. 345–352, 2010.
- K. Li, A. Singh, D. R. Crooks et al., “Expression of human frataxin is regulated by transcription factors SRF and TFAP2,” PLoS ONE, vol. 5, no. 8, Article ID e12286, 2010.